The CB Insights Q1 2025 Artificial Intelligence Report shows a rebound in global AI funding, up 45% quarter-over-quarter to $13.1B, led by OpenAI’s $2.6B secondary sale. GenAI remains dominant, with 80% of top deals in this space. Notable trends include rising investments in agent infrastructure, open-source model development, and custom chips. AI’s role in drug discovery gained traction with deals like Xaira Therapeutics’ \$1B Series A. Enterprise buyers are shifting from experimentation to evaluating ROI, prompting startups to emphasize reliability, data integration, and specific use cases .

Join for free to read